Stocktwits on MSN8d
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same PageShares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...
The Student Government Association (SGA) meeting on Tuesday, Feb. 11, featured new updates for students, including the ...
Rep. Ro Khanna (D-Calif.) joins 'Squawk Box' to discuss President Trump's third week back in office, DOGE and Elon Musk's efforts to downsize the federal government, working across the aisle in the ...
David Risinger is an analyst at Leerink Partners. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected ...
Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF following the termination of Eli Lilly (NYSE:LLY)'s study. However, the firm ...
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...
17d
Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...
Hosted on MSN1mon
Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here’s whyWall Street’s forecasts were missed across the board. Despite this setback, Leerink Partners analyst David Risinger maintained his positive outlook on Eli Lilly, citing promising developments in ...
Among the area players who signed athletic scholarships on National Signing Day was American-Statesman offensive Player of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback